World Asset Management Inc acquired a new position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 4,004 shares of the life sciences company’s stock, valued at approximately $218,000.

Several other hedge funds have also bought and sold shares of IART. ProShare Advisors LLC boosted its stake in Integra LifeSciences Holdings Corporation by 51.2% in the first quarter. ProShare Advisors LLC now owns 8,350 shares of the life sciences company’s stock worth $352,000 after buying an additional 2,829 shares during the last quarter. Profund Advisors LLC boosted its stake in Integra LifeSciences Holdings Corporation by 65.5% in the first quarter. Profund Advisors LLC now owns 11,349 shares of the life sciences company’s stock worth $478,000 after buying an additional 4,492 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Integra LifeSciences Holdings Corporation by 97.8% in the first quarter. Fisher Asset Management LLC now owns 1,031,310 shares of the life sciences company’s stock worth $43,449,000 after buying an additional 509,980 shares during the last quarter. First Manhattan Co. acquired a new stake in Integra LifeSciences Holdings Corporation during the first quarter worth $117,000. Finally, Northwest Investment Counselors LLC boosted its stake in Integra LifeSciences Holdings Corporation by 100.0% in the first quarter. Northwest Investment Counselors LLC now owns 7,880 shares of the life sciences company’s stock worth $332,000 after buying an additional 3,940 shares during the last quarter. 85.66% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Holdings Corporation (IART) opened at 50.22 on Friday. The firm’s 50 day moving average price is $52.04 and its 200-day moving average price is $47.26. Integra LifeSciences Holdings Corporation has a 1-year low of $40.51 and a 1-year high of $88.86. The stock has a market cap of $3.92 billion, a price-to-earnings ratio of 61.24 and a beta of 0.73.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The business had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. The business’s quarterly revenue was up 13.2% compared to the same quarter last year. On average, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/20/world-asset-management-inc-acquires-shares-of-4004-integra-lifesciences-holdings-corporation-iart.html.

A number of analysts have recently weighed in on the company. BidaskClub cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. set a $60.00 price objective on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald assumed coverage on Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They issued an “overweight” rating and a $65.00 price objective for the company. Zacks Investment Research cut Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, June 28th. Finally, UBS AG reissued a “buy” rating and issued a $60.00 price objective (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Friday, June 9th. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Integra LifeSciences Holdings Corporation presently has a consensus rating of “Buy” and a consensus target price of $52.63.

In other news, Director Stuart Essig sold 140,000 shares of the stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $48.01, for a total transaction of $6,721,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald E. Morel, Jr. bought 2,500 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $49.29 per share, with a total value of $123,225.00. Following the purchase, the director now directly owns 29,612 shares of the company’s stock, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. Insiders have bought 17,550 shares of company stock valued at $864,842 in the last quarter. Insiders own 21.50% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.